News
NTRBW
1.800
+5.40%
0.092
Nutriband Issues Letter to Shareholders
Barchart · 12/31/2024 06:00
Weekly Report: what happened at NTRBW last week (1223-1227)?
Weekly Report · 12/30/2024 10:17
NUTRIBAND INC: TARGETING TO FILE FOR FDA APPROVAL FOR AVERSA™ FENTANYL IN FIRST HALF OF 2025
Reuters · 12/27/2024 14:25
Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology
Barchart · 12/27/2024 08:25
Weekly Report: what happened at NTRBW last week (1216-1220)?
Weekly Report · 12/23/2024 10:21
Weekly Report: what happened at NTRBW last week (1209-1213)?
Weekly Report · 12/16/2024 10:22
Weekly Report: what happened at NTRBW last week (1202-1206)?
Weekly Report · 12/09/2024 10:21
Weekly Report: what happened at NTRBW last week (1125-1129)?
Weekly Report · 12/02/2024 10:21
Nutriband Inc. Announces Patent Grant for AVERSA™ Abuse Deterrent Transdermal Technology in Hong Kong
Barchart · 11/27/2024 16:16
NUTRIBAND RECEIVES HONG KONG PATENT NOTICE OF PUBLICATION FOR ITS AVERSA™ ABUSE DETERRENT TRANSDERMAL TECHNOLOGY
Reuters · 11/27/2024 12:03
Weekly Report: what happened at NTRBW last week (1118-1122)?
Weekly Report · 11/25/2024 10:16
Weekly Report: what happened at NTRBW last week (1111-1115)?
Weekly Report · 11/18/2024 10:15
Weekly Report: what happened at NTRBW last week (1104-1108)?
Weekly Report · 11/11/2024 10:21
Weekly Report: what happened at NTRBW last week (1028-1101)?
Weekly Report · 11/04/2024 10:21
Weekly Report: what happened at NTRBW last week (1021-1025)?
Weekly Report · 10/28/2024 10:16
Weekly Report: what happened at NTRBW last week (1014-1018)?
Weekly Report · 10/21/2024 10:14
Weekly Report: what happened at NTRBW last week (1007-1011)?
Weekly Report · 10/14/2024 10:30
Weekly Report: what happened at NTRBW last week (0930-1004)?
Weekly Report · 10/07/2024 10:23
Weekly Report: what happened at NTRBW last week (0923-0927)?
Weekly Report · 09/30/2024 10:20
Weekly Report: what happened at NTRBW last week (0916-0920)?
Weekly Report · 09/23/2024 10:19
More
Webull provides a variety of real-time NTRBW stock news. You can receive the latest news about Nutriband through multiple platforms. This information may help you make smarter investment decisions.
About NTRBW
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.